Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
Authors:
Open Access
- 1 October 2019
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 9 (4) , 1-9
Abstract
Metabolic abnormalities are proposed to contribute to pulmonary arterial as well as right ventricular remodelling in pulmonary arterial hypertension. Among the proposed abnormalities are altered glucose and lipid processing, mitochondrial malfunction, oxidative stress as well as vitamin D and iron abnormalities. In the present study, we investigated 11 metabolic plasma biomarkers, with the hypothesis that metabolic proteins may mirror disease severity in pulmonary arterial hypertension. Using proximity extension assays, plasma metabolic biomarkers were measured in 48 pulmonary arterial hypertension patients at diagnosis and, in 33 of them, at an early treatment follow‐up, as well as in 16 healthy controls. Among the studied metabolic biomarkers, plasma fibroblast growth factor‐23 (p < 0.001), fibroblast growth factor‐21 (p < 0.001), fatty acid binding protein 4 (p < 0.001) and lectin‐like oxidised low‐density lipoprotein receptor 1 (p < 0.001) were increased and paraoxonase‐3 was decreased (p < 0.001) in pulmonary arterial hypertension at diagnosis versus controls. Fibroblast growth factor‐23 showed the strongest correlations to studied clinical parameters and was therefore selected for further analyses. Fibroblast growth factor‐23 correlated specifically to mean right atrial pressure (r = 0.67, p < 0.001), six‐min walking distance (r = −0.66, p < 0.001), NT‐proBNP (r = 0.64, p < 0.001), venous oxygen saturation (r = −0.61, p < 0.001), cardiac index (r = −0.39, p < 0.007) and pulmonary vascular resistance (r = 0.37, p < 0.01). Fibroblast growth factor‐23 correlated moreover to ESC/ERS (r = 0.72, p < 0.001) and the REVEAL risk score (r = 0.61, p < 0.001). Comparing early treatment follow‐up with baseline, fibroblast growth factor‐23 decreased (p < 0.02), with changes in fibroblast growth factor‐23 correlating to changes in six‐min walking distance (r = −0.56, p < 0.003), venous oxygen saturation (r = −0.46, p < 0.01), pulmonary vascular resistance (r = 0.43, p < 0.02), mean right atrial pressure (r = 0.38, p < 0.04) and cardiac index (r = −0.39, p < 0.04). Elevated plasma fibroblast growth factor‐23 levels at pulmonary arterial hypertension diagnosis were associated with worse haemodynamics and a higher risk profile, and were decreased after the administration of pulmonary arterial hypertension‐specific treatment.Keywords
Funding Information
- Actelion Pharmaceuticals
This publication has 40 references indexed in Scilit:
- Metabolic actions of FGF21: molecular mechanisms and therapeutic implicationsActa Pharmaceutica Sinica B, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Serum FGF-21 Levels in Type 2 Diabetic PatientsEndocrine Research, 2011
- Plasma Levels of High-Density Lipoprotein Cholesterol and Outcomes in Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2010
- The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricleJournal of Molecular Medicine, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Pathology of Pulmonary HypertensionClinics in Chest Medicine, 2007
- Alterations of cellular bioenergetics in pulmonary artery endothelial cellsProceedings of the National Academy of Sciences, 2007
- Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell ApoptosisCirculation Research, 2004